C4 Therapeutics Inc (CCCC) - Net Assets
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has net assets worth $234.25 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($328.86 Million) and total liabilities ($94.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CCCC goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $234.25 Million |
| % of Total Assets | 71.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | -34.14% |
| 10-Year Change | N/A |
| Growth Volatility | 24.03 |
C4 Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See CCCC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for C4 Therapeutics Inc (2018–2025)
The table below shows the annual net assets of C4 Therapeutics Inc from 2018 to 2025. For live valuation and market cap data, see C4 Therapeutics Inc (CCCC) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $256.59 Million | +18.80% |
| 2024-12-31 | $215.99 Million | -12.24% |
| 2023-12-31 | $246.11 Million | -14.91% |
| 2022-12-31 | $289.23 Million | -25.76% |
| 2021-12-31 | $389.61 Million | +38.75% |
| 2020-12-31 | $280.79 Million | +350.79% |
| 2019-12-31 | $-111.96 Million | -40.39% |
| 2018-12-31 | $-79.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to C4 Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65530400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.00% |
| Other Comprehensive Income | $50.00K | 0.02% |
| Other Components | $995.22 Million | 387.87% |
| Total Equity | $256.59 Million | 100.00% |
C4 Therapeutics Inc Competitors by Market Cap
The table below lists competitors of C4 Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Qijing Machinery
SHG:603677
|
$404.72 Million |
|
Hyundai Motor Securities Co. Ltd.
KO:001500
|
$404.79 Million |
|
Syncmold Enterprise Corp
TW:1582
|
$404.98 Million |
|
HaiXin Foods Co Ltd
SHE:002702
|
$405.00 Million |
|
Zhejiang Zhe Kuang Heavy Industry
SHE:300837
|
$404.63 Million |
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
$404.51 Million |
|
Tianjin Realty Development Group Co Ltd
SHG:600322
|
$404.50 Million |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
$404.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in C4 Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 215,986,000 to 256,587,000, a change of 40,601,000 (18.8%).
- Net loss of 104,994,000 reduced equity.
- Share repurchases of 193,000 reduced equity.
- New share issuances of 126,211,000 increased equity.
- Other comprehensive income decreased equity by 3,000.
- Other factors increased equity by 19,580,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-104.99 Million | -40.92% |
| Share Repurchases | $193.00K | -0.08% |
| Share Issuances | $126.21 Million | +49.19% |
| Other Comprehensive Income | $-3.00K | -0.0% |
| Other Changes | $19.58 Million | +7.63% |
| Total Change | $- | 18.80% |
Book Value vs Market Value Analysis
This analysis compares C4 Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.89 | $3.84 | x |
| 2019-12-31 | $-2.60 | $3.84 | x |
| 2020-12-31 | $6.52 | $3.84 | x |
| 2021-12-31 | $8.46 | $3.84 | x |
| 2022-12-31 | $5.92 | $3.84 | x |
| 2023-12-31 | $4.96 | $3.84 | x |
| 2024-12-31 | $3.11 | $3.84 | x |
| 2025-12-31 | $3.10 | $3.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently C4 Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -292.08%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.40x
- Recent ROE (-40.92%) is below the historical average (-29.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -81.14% | 0.13x | 0.00x | $-7.74 Million |
| 2019 | 0.00% | -159.48% | 0.18x | 0.00x | $-22.90 Million |
| 2020 | -23.62% | -199.83% | 0.08x | 1.43x | $-94.41 Million |
| 2021 | -21.53% | -183.23% | 0.09x | 1.30x | $-122.85 Million |
| 2022 | -44.32% | -412.19% | 0.07x | 1.49x | $-157.10 Million |
| 2023 | -53.83% | -638.34% | 0.06x | 1.53x | $-157.10 Million |
| 2024 | -48.76% | -295.96% | 0.10x | 1.62x | $-126.91 Million |
| 2025 | -40.92% | -292.08% | 0.10x | 1.40x | $-130.65 Million |
Industry Comparison
This section compares C4 Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| C4 Therapeutics Inc (CCCC) | $234.25 Million | 0.00% | 0.40x | $404.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more